Firm at a glance
Cinven is a platform private equity firm with more than €50 billion in total funds raised, per its own website [S1].
What they buy
Cinven’s portfolio spans six sectors, with concentrations in business services, healthcare, financial services, technology/media/telecom (TMT), industrials, and consumer businesses [S2]. The firm maintains a diversified portfolio of approximately 45 holdings across Europe and North America, including both large-scale platforms and specialized service providers [S2]. Recent activity suggests continued interest in healthcare services, industrial carve-outs, and technology-enabled business services [S3].
Portfolio
Business Services
Accumin, Alter Domus (also Financial Services), Amara NZero, Archer (also TMT), Artefact, Barentz II, Domia Group, Envirotainer (also Healthcare and Industrials), Flint Global, HBX Group, JLA, OMNES Education, TK Elevator (also Industrials) [S2].
Healthcare
BioAgilytix, LGC, National Seating & Mobility, Nutrisens, Regenity Biosciences, STADA, SYNLAB [S2].
Financial Services
Compre (Strategic Financials Fund), Finaxy Group (Strategic Financials Fund), Grant Thornton, IFGL (Strategic Financials Fund), NewDay, Objectway, Policy Expert (Strategic Financials Fund), Säkra, True Potential (also TMT) [S2].
TMT
Allegro (also Consumer), group.One, idealista, MasOrange, RTB House, Smart Communications, Taxwell, think-cell, Ufinet International II [S2].
Industrials
Arxada, Envu, Master Builders Solutions [S2].
Consumer
Fressnapf Group, PPF, Restaurant Brands Europe, Vitamin Well [S2].
Recent activity (last 24 months)
* Vitamin Well Group combination with EMPWR, 2024 [S3]
* Ongoing Warehouse acquisition, 2024 [S3]
* KONE and TKE combination (exit), 2024 [S3]
* Envu acquisition, 2024 [S3]
* Regenity Biosciences acquisition, 2024 [S3]
How this firm fits a seller
Cinven’s portfolio composition suggests the firm targets established businesses with international growth potential across multiple sectors [S2]. The firm’s 2024 transactions include both platform acquisitions and a major exit, indicating active portfolio management [S3]. For owner-operators in business services, healthcare, or financial services seeking a buyer with substantial capital resources (funds raised exceeding €50 billion), Cinven represents a potential fit [S1][S2]. The firm’s portfolio includes both founder-led businesses and corporate carve-outs, suggesting flexibility in deal structures [S2].
Sources
[S1] https://www.cinven.com (as of 2026-01-20)
[S2] https://www.cinven.com/portfolio/ (as of 2026-01-20)
[S3] https://www.cinven.com/news-insights/ (as of 2026-01-20)
Frequently asked questions
Does Cinven buy healthcare businesses?
Yes, Cinven maintains an active healthcare portfolio with seven holdings as of early 2026, including BioAgilytix, LGC, National Seating & Mobility, Nutrisens, Regenity Biosciences, STADA, and SYNLAB [S2]. The firm acquired Regenity Biosciences in 2024, demonstrating continued investment in the sector [S3].
What companies has Cinven acquired recently?
Recent acquisitions include Envu (an industrials business), Regenity Biosciences (healthcare), and Ongoing Warehouse, all completed in 2024 [S3]. The firm also announced a combination of portfolio company Vitamin Well Group with EMPWR in 2024 [S3].
Where is Cinven based and how big is the firm?
Cinven has raised more than €50 billion in total funds across its history, per public sources as of January 2026 [S1]. Specific headquarters location and office details were not surfaced in available public materials.
Is Cinven still actively acquiring?
Yes, Cinven completed multiple acquisitions throughout 2024, including Envu, Regenity Biosciences, and Ongoing Warehouse, indicating ongoing deal activity [S3].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.